Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 10, 2006, Pages 691-696

  Ye, Ping ^a   Yang, W ^a   Wu, S M ^a   Sheng, L ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cardiac hypertrophy; Cytokines; Inflammation; PPAR

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN II; ANIMALS; ANTI-INFLAMMATORY AGENTS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; CELLS, CULTURED; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUCINE; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PPAR GAMMA; RATS; RATS, WISTAR; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 33846873666     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2006.28.10.1037500     Document Type: Article

References (24)

1. Levy, D., Garrison, R.J., Savage, D.D. et al. Prognostic implications of echocardiographically determined left-ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322: 1561-6.
2. Lorell, B.H., Carabello, B.A. Left ventricular hypertrophy- pathogenesis, detection, and prognosis. Circulation 2000, 102: 470-9.
3. Schoonjans, K., Martin, G., Staels, B. et al. Peroxisome proliferator-activated receptors, orphans with ligands and function. Curr Opin Lipidol 1997, 8: 159-66.
4. Plutzky, J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003, 92 (Suppl): 34J-41J.
5. Asakawa, M., Takano, H., Nagai, T. et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002, 105: 1240-6.
6. Daynes, R., Jones, D. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2: 748-59.
7. Ricote, M., Li, A.C., Willson, T.M. et al. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature 1998, 391: 79-82.
8. Jiang, C., Ting, A.T., Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391: 82-6.
9. Simpson, P., Savion, S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Circ Res 1982; 50: 101-16.
10. Shioi, T., Matsumori, A., Kihara, Y. et al. Increased expression of interleukin-1beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 1997; 81: 664-71.
11. Harada, E., Nakagawa, O., Yoshimura, M. et al. Effect of interleukin-1beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol 1999, 31: 1997-2006.
12. Sano, M., Fukuda, K., Kodama, H. IL-6 family of cytokines mediate Ang II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000, 275: 29717-23.
13. Tanaka, T., Kanada, T., Takahashi, T. IL-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes. J Int Med Res 2004, 32: 57-61.
14. Ancey, C., Menet, E., Corbi, P. et al. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc Res 2003, 59: 78-85.
15. Kato, J., Etoh, T., Kitamura, K. et al. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Am J Hypertens 2005, 18: 354-7.
16. Luchner, A., Muders, F., Dietl, O. et al. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovas Res 2001, 51: 601-7.
17. Plutzky, J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003, 92(Suppl): 34J-41J.
18. Hsueh, W., Law, R. The central role of fat and effect of peroxisome proliferator-activated receptors-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003, 92(Suppl): 3J-9J.
19. Xu, Y., Lu, L., Greyson, C. et al. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptors-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes 2003, 52: 1187-94.
20. Wayman, N.S., Hattori, Y., McDonald, M.C. et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002, 16: 1027-40.
21. Takano, H., Zou, Y., Akasawa, H. et al. Inhibitory molecules in signal transduction pathways of cardiac hypertrophy. Hypertens Res 2002, 25: 491-8.
22. Takkano, H., Nagai, T., Asakawa, M. et al. Proxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000, 87: 596-602.
23. Yamamoto, K., Ohki, R., Lee, R.T. et al. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation, 2001, 104: 1670-75.
24. Koh, K.K., Han, S.H., Quon, M.J. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol 2005, 46: 1978-85.